title: Tumor infiltrating lymphocytes in ovarian cancer.
abstract: Several improvements in ovarian cancer treatment have been achieved in recent years, both in surgery and in combination chemotherapy with targeting. However, ovarian tumors remain the women's cancers with highest mortality rates. In this scenario, a pivotal role has been endorsed to the immunological environment and to the immunological mechanisms involved in ovarian cancer behavior. Recent evidence suggests a loss of the critical balance between immune-activating and immune-suppressing mechanisms when oncogenesis and cancer progression occur. Ovarian cancer generates a mechanism to escape the immune system by producing a highly suppressive environment. Immune-activated tumor infiltrating lymphocytes (TILs) in ovarian tumor tissue testify that the immune system is the trigger in this neoplasm. The TIL mileau has been demonstrated to be associated with better prognosis, more chemosensitivity, and more cases of optimal residual tumor achieved during primary cytoreduction. Nowadays, scientists are focusing attention on new immunologically effective tumor biomarkers in order to optimize selection of patients for recruitment in clinical trials and to identify relationships of these biomarkers with responses to immunotherapeutics. Assessing this point of view, TILs might be considered as a potent predictive immunotherapy biomarker.
authors.affiliation: Department of Gynecologic-Obstetrical and Urologic Sciences, "Sapienza" University of Rome, Italy E-mail : marialuisa.gasparri@uniroma1.it.
authors.forename: Maria Luisa
authors.initials: ML
authors.lastname: Gasparri
authors.forename: Rukset
authors.initials: R
authors.lastname: Attar
authors.forename: Innocenza
authors.initials: I
authors.lastname: Palaia
authors.forename: Giorgia
authors.initials: G
authors.lastname: Perniola
authors.forename: Claudia
authors.initials: C
authors.lastname: Marchetti
authors.forename: Violante
authors.initials: V
authors.lastname: Di Donato
authors.forename: Ammad Ahmad
authors.initials: AA
authors.lastname: Farooqi
authors.forename: Andrea
authors.initials: A
authors.lastname: Papadia
authors.forename: Pierluigi Benedetti
authors.initials: PB
authors.lastname: Panici
mesh_terms: D000818:Animals; D014408:Biomarkers, Tumor / Q000378:metabolism*; D005260:Female; D006801:Humans; D007167:Immunotherapy; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology*; D010051:Ovarian Neoplasms / Q000276:immunology* / Q000473:pathology / Q000628:therapy
chemical_list: D014408:Biomarkers, Tumor